Erica L. Mayer

9.7k citations

144 papers · 4.7k indexed · 1 hit paper · h-index 31

Oncology top 1%
- Cancer Treatment and Pharmacology 50
- HER2/EGFR in Cancer Research 39
- Cancer Risks and Factors 10
- PARP inhibition in cancer therapy 9
Family Practice top 1%
Cancer Research top 1%
- Breast Cancer Treatment Studies 47
- Cancer Genomics and Diagnostics 15
Pulmonary and Respiratory Medicine top 2%
- Advanced Breast Cancer Therapies 54
Hematology top 5%
Genetics
- Estrogen and related hormone effects 11

Co-authors: Ramesh A. Shivdasani Stuart H. Orkin Eric P. Winer Harold J. Burstein Ann H. Partridge Ian E. Krop Aviva G. Asnis-Alibozek Hope S. Rugo
Cited by: Oncology Family Practice Cancer Research
Journals: Nature (1 paper)Nucleic Acids Research (1 paper)Journal of Biological Chemistry (1 paper)
Partner nations: United States Italy Germany

In The Last Decade

Erica L. Mayer

128 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Erica L. Mayer

Since Specialization

Citations

This map shows the geographic impact of Erica L. Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica L. Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica L. Mayer more than expected).

Fields of papers citing papers by Erica L. Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica L. Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica L. Mayer. The network helps show where Erica L. Mayer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erica L. Mayer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erica L. Mayer Line = papers co-authored together Erica L. Mayer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	DirectHRD enables sensitive scar-based classification of homologous recombination deficiency Nucleic Acids Research ·Ruolin Liu,Eugenia Roberts,Heather A. Parsons,Elizabeth H. Stover,Atish D. Choudhury,Justin Rhoades,Timothy Blewett,David D. Yang,Joyce F Liu,Erica L. Mayer,Viktor A. Adalsteinsson	2025	2
2	Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021 npj Breast Cancer ·Alexandra Thomas,Anthony Rhoads,Erica L. Mayer,Séamus O’Reilly,Nadia Harbeck,Giuseppe Curigliano,Yang Zhou,Virginie Adam,Nancy Chan,Kristin M. Conway,Michail Ignatiadis,Kevin Kalinsky,Angela DeMichele,Paul A. Romitti	2025	0
3	Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109) ESMO Open ·Elisa Agostinetto,Georg Pfeiler,Dominik Hlauschek,Erica L. Mayer,Matteo Lambertini,Evandro de Azambuja,M. Bellet-Ezquerra,Jane Meisel,Gábor Rubovszky,Nicholas Zdenkowski,Yelena Novik,Manuel Ruíz‐Borrego,Karen A. Gelmon,Eleftherios P. Mamounas,Hiroji Iwata,Dongrui R. Lu,Lidija Soelkner,Christian Fesl,Michael Gnant,Angela DeMichele	2025	1
4	Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2− early breast cancer: a discrete choice survey study Breast Cancer Research and Treatment ·Erica L. Mayer,Mary Lou Smith,Annie Guérin,Dominick Latrémouille-Viau,Nisha C. Hazra,Yan Meng,Wendi Qu,Remi Bellefleur,Vaidyanathan Ganapathy,Liz Santarsiero,Robert Morlock,Maryam B. Lustberg	2025	1
5	Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study ESMO Open ·Chiara Corti,Xun Chu,Pedro Exman,David Kline,Nolan Priedigkeit,Erica L. Mayer,A.G. Waks,Melissa E. Hughes,Daniel L. Abravanel,Antonio Giordano,G. Curigliano,NU Lin,Tari A. King,Rinath Jeselsohn,Danielle K. Manning,Deborah Dillon,Elizabeth A. Mittendorf,Nabihah Tayob,Sara M. Tolaney	2025	0
6	Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer Cancer Research ·Rinath Jeselsohn,Jingxin Fu,Yue Ren,Reshma Mahtani,X. Cynthia,Angela DeMichele,Massimo Cristofanilli,Jane Meisel,Kathy L. Miller,Yara Abdou,Elizabeth Riley,Rubina Qamar,Priyanka Sharma,Sonya Reid,Naomi Y. Ko,Yuan Liu,Harold J. Burstein,Michelle K. DeMeo,Sara M. Tolaney,Erica L. Mayer	2024	1
7	Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502 npj Breast Cancer ·Daniel G. Stover,Roberto Salgado,Oleksander Savenkov,Karla V. Ballman,Erica L. Mayer,Mark Jesus M. Magbanua,Sherene Loi,Mark Vater,Kristyn Glover,Mark A. Watson,Yujia Wen,W. Fraser Symmans,Charles M. Perou,Lisa A. Carey,Ann H. Partridge,Hope S. Rugo	2024	4
8	A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer Clinical Cancer Research ·Antonio Giordano,Priya Kumthekar,Qingchun Jin,Busem Binboğa Kurt,Siyang Ren,Tianyu Li,José Pablo Leone,Elizabeth A. Mittendorf,Alyssa Pereslete,Laura Sharp,Raechel Davis,Molly DiLullo,Nabihah Tayob,Erica L. Mayer,Eric P. Winer,Sara M. Tolaney,Nancy U. Lin	2024	2
9	The state of the science of oral selective oestrogen receptor degraders The Lancet Oncology ·Kristina Fanucci,Erica L. Mayer	2024	1
10	Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2− breast cancer The Oncologist ·Shadab A. Rahman,Hanneke Poort,Deborah Schrag,Stephanie Tung,Eric S. Zhou,Aleta Wiley,Lauren B. Finkelstein,Elkhansaa Elguenaoui,Moira Nolan,Erica L. Mayer,Hadine Joffe	2024	0
11	Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial Annals of Surgical Oncology ·Charity C. Glass,Robert M. Pride,Rachel A. Freedman,Erica L. Mayer,Esther R. Ogayo,Mariana Chávez‐MacGregor,Tari A. King,Elizabeth A. Mittendorf,Olga Kantor	2023	0
12	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers Clinical Cancer Research ·Felipe Batalini,D. Gulhan,Victor Y. Mao,Antuan V. Tran,Madeline Polak,Niya Xiong,Nabihah Tayob,Nadine Tung,Eric P. Winer,Erica L. Mayer,Stian Knappskog,Per Eystein Lønning,Ursula A. Matulonis,Panagiotis A. Konstantinopoulos,David B. Solit,Helen Won,Hans Petter Eikesdal,Peter J. Park,Gerburg M. Wulf	2022	22
13	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer Clinical Cancer Research ·Siang‐Boon Koh,Kenneth N. Ross,Steven J. Isakoff,Nsan Melkonjan,Lei He,Karina J. Matissek,Andrew Schultz,Erica L. Mayer,Tiffany A. Traina,Lisa A. Carey,Hope S. Rugo,Minetta C. Liu,Vered Stearns,Adam Langenbucher,Srinivas Vinod Saladi,Sridhar Ramaswamy,Michael S. Lawrence,Leif W. Ellisen	2021	16
14	Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel Radiology ·Anton S. Becker,Rocío Pérez-Johnston,Sona A. Chikarmane,Melissa Chen,Maria El Homsi,Kimberly Feigin,Katherine Gallagher,Ehab Y. Hanna,Marshall E. Hicks,Ahmet Turan Ilıca,Erica L. Mayer,Atul B. Shinagare,Randy Yeh,Marius E. Mayerhoefer,Hedvig Hricak,Hebert Alberto Vargas	2021	84
15	A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer Breast Cancer Research and Treatment ·Otto Metzger,Anita Giobbie‐Hurder,Nancy U. Lin,Meredith Faggen,Steven E. Come,Thomas H. Openshaw,Michael Constantine,Jeanna Walsh,Rachel A. Freedman,Bryan P. Schneider,Harold J. Burstein,Erica L. Mayer	2020	6
16	LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer Annals of Oncology ·Erica L. Mayer,M.I. Gnant,Angela DeMichele,Miguel Martín,Harold J. Burstein,Aleix Prat,Gábor Rubovszky,Kathy D. Miller,Georg Pfeiler,Eric P. Winer,Nicholas Zdenkowski,D. Mark Anderson,Zbigniew Nowecki,Sibylle Loibl,Hannes Fohler,Otto Metzger,Debora Fumagalli,Kathy Puyana Theall,Christian Fesl,Amylou C. Dueck	2020	23
17	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer Clinical Cancer Research ·Brian D. Lehmann,Vandana G. Abramson,Melinda E. Sanders,Erica L. Mayer,Tufia C. Haddad,Rita Nanda,Catherine Van Poznak,Anna Maria Storniolo,Julie R. Nangia,Paula I. González-Ericsson,Violeta Sánchez,Kimberly N. Johnson,Richard G. Abramson,Sheau‐Chiann Chen,Yu Shyr,Carlos L. Arteaga,Antonio C. Wolff,Jennifer A. Pietenpol	2019	113
18	PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer Annals of Oncology ·Erica L. Mayer,Angela DeMichele,Georg Pfeiler,W Barry,Otto Metzger,Priya Rastogi,F. Symmans,Harold J. Burstein,Kathy D. Miller,Sibylle Loibl,Sabine Schmatloch,Theodora Goulioti,Dimitrios Zardavas,Christian Fesl,María Koehler,Cynthia Huang Bartlett,Xin Huang,Martine Piccart,Eric P. Winer,Michael Gnant	2017	7
19	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers Clinical Cancer Research ·Mark Jesus M. Magbanua,Lisa A. Carey,Amy DeLuca,Jimmy Hwang,Janet H. Scott,Mothaffar F. Rimawi,Erica L. Mayer,P. Kelly Marcom,Minetta C. Liu,Francisco J. Esteva,John W. Park,Hope S. Rugo	2014	32
20	A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer Breast Cancer Research and Treatment ·Nancy U. Lin,Davinia Seah,Rebecca Gelman,Stephen DeSantis,Erica L. Mayer,Steven J. Isakoff,Pamela J. DiPiro,Ian E. Krop,Steven E. Come,Douglas Weckstein,Eric P. Winer,Harold J. Burstein	2013	15

About Erica L. Mayer

Erica L. Mayer is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 144 papers that have together received 4.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (54 papers), Cancer Treatment and Pharmacology (50 papers), Breast Cancer Treatment Studies (47 papers), HER2/EGFR in Cancer Research (39 papers), Cancer Genomics and Diagnostics (15 papers), Estrogen and related hormone effects (11 papers), Cancer Risks and Factors (10 papers) and PARP inhibition in cancer therapy (9 papers). The work is most often cited by research in Oncology (2.6k citations), Family Practice (201 citations) and Cancer Research (1.2k citations). Erica L. Mayer has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Ramesh A. Shivdasani, Stuart H. Orkin, Eric P. Winer, Harold J. Burstein, Ann H. Partridge, Ian E. Krop, Aviva G. Asnis-Alibozek, Hope S. Rugo, Lisa A. Carey and Minetta C. Liu. Their work appears in journals such as Nature, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact